Regaining Control of “Indar”: Protecting Strategic Drug Production and the State’s Interests
The State Property Fund of Ukraine has regained full control over the strategic pharmaceutical enterprise PJSC “Indar”—Ukraine’s only full-cycle insulin manufacturer with state ownership. Despite holding a 70.7% stake, the state had been artificially excluded from actual management of the asset for years due to court rulings and the actions of the previous management.
Dmytro Natalukha, head of the State Property Fund of Ukraine (SPFU), discussed the current state of affairs at the plant, the initial results of audits, and the tasks facing the new management team during a media briefing held directly at the enterprise.
“Despite the state’s majority stake, it was unable to influence what was happening at the enterprise due to a series of legal and court rulings. It appears that the former director, along with others, did everything possible to isolate the state from participating in the management and control of this strategic enterprise,” emphasized Dmytro Natalukha.
As of now, the new team has already uncovered numerous and significant violations:
Over UAH 72 million in debt owed to “Indar” by a single private counterparty, of which nearly UAH 69 million is unrepaid interest-free financial assistance.
Documents have been uncovered regarding this debtor company’s preparations for a staged bankruptcy.
Direct family ties have been documented between the management of the contractor firm and officials from the plant’s previous management.
The state’s key priority is the uninterrupted operation of production lines and the safety of Ukrainian patients.
“Our task is precisely to ensure that patients do not even notice the change in leadership at Indar. The primary and most important task is to prevent sabotage, to prevent the plant from shutting down, and to prevent a deterioration in its working and production conditions,” noted the head of the State Property Fund.
Action plan for the near future:
Maintaining the full production cycle and ensuring a stable supply of insulin to the healthcare system.
Audit and assessment: The supervisory board, together with the new management, is conducting a comprehensive management and financial audit to determine the plant’s actual condition and update the valuation of the state’s stake.
Restoring market positions and ensuring quality control: modernizing technological processes, strictly enforcing standards, and providing Ukrainians with affordable domestically produced medications.
“This is very important and significant for us: the state is capable of protecting its interests and regaining control over a strategic enterprise. I hope we will demonstrate that the state is capable of restoring effective operations and production—and of making this enterprise a truly competitive player in the market,” concluded Dmytro Natalukha.